Compare Medpace Holdings Inc (MEDP) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs MINISO Group Holding Ltd — how do they compare? Medpace Holdings Inc trades at $582 (market cap $16.66B), while MINISO Group Holding Ltd trades at $11.78 (market cap $3.58B). The key difference: Medpace Holdings Inc is far larger — about 4.7× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.6% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MNSO | |
|---|---|---|
Market Cap | $16.66B | $3.58B |
Sector | Technology | Technology |
52-Week High | $620.59 | $26.63 |
52-Week Low | $393.42 | $11.30 |
Enterprise Value | $16.28B | $4.25B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 1.41% today but maintains a bullish technical outlook with strong moving average support. The company demonstrates robust fundamentals with 17.2% YoY revenue growth in Q2 2026 and consistent earnings beats, though valuation metrics remain elevated with a P/E of 35.08. Recent news highlights record Q2 bookings and raised 2026 guidance, while technical indicators show the stock trading near pivot point resistance at $598.
MEDP presents a growth opportunity with strong operational performance and positive analyst sentiment, though premium valuation and potential legal scrutiny pose risks. The stock's technical strength and fundamental momentum support further upside toward the $692 price target, but investors should monitor the ongoing legal investigation and valuation compression risks in a volatile market environment.
MNSO trades at $11.9, down 1.16% on the day, with a bearish technical signal from moving averages despite a neutral oscillator stance. The company reported strong Q1 2026 earnings that beat expectations, with revenue growth of 28.5% year-over-year, and announced a $2 billion share repurchase program in June 2026 to enhance shareholder value. Valuation ratios appear reasonable with a P/E of 12.02 and P/S of 1.09, while profitability metrics show a net income margin of 8.98% and ROE of 18.88%.
The outlook is mixed; analyst consensus is 75% buy with potential upside from operational execution and buybacks, but risks include margin pressure from rising expenses and competitive threats in the value retail sector. The stock's recent underperformance versus the market highlights investor caution amid earnings volatility, requiring close monitoring of future quarterly results for sustained growth confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
